KRMD
KORU Medical Systems, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Sell
-48/100
Last price
3.00
▼ 0.01 (0.33%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
3.01
Day high
3.02
Day low
2.95
Volume
129.06K
Market cap
$137.80M
P/E (TTM)
—
52W range
2.86 – 6.61
Trailing performance
Returnvs SPY
1W
-0.17%
-2.1%
1M
-7.69%
-8.8%
3M
-32.28%
-36.8%
6M
-29.25%
-47.4%
YTD
-48.36%
-62.6%
1Y
-22.08%
-38.5%
3Y
+11.11%
-71.1%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on KRMD open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
3.79M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Oct 1, 26 | FLETCHER R JOHN Director |
STOCK | 7.68K | $22.50K | Direct |
| Oct 1, 26 | CASCELLA ROBERT A Director |
STOCK | 5.12K | $15.00K | Direct |
| Oct 1, 26 | MATIN SHAHRIAR Director |
STOCK | 5.12K | $15.00K | Direct |
| Oct 1, 26 | WHOLIHAN EDWARD Director |
STOCK | 5.12K | $15.00K | Direct |
| Oct 1, 26 | FRENCH DONNA Director |
STOCK | 5.12K | $15.00K | Direct |
| Sep 8, 26 | KALBERMATTEN ADAM R Officer |
BUY | 32.00K | $101.12K | Direct |
| Jul 28, 26 | KALBERMATTEN ADAM R Officer |
— | 75.00K | — | Direct |
| Jul 1, 26 | FLETCHER R JOHN Chairman of the Board |
STOCK | 5.36K | $22.50K | Direct |
| Jul 1, 26 | CASCELLA ROBERT A Director |
STOCK | 3.57K | $15.00K | Direct |
| Jul 1, 26 | MATIN SHAHRIAR Director |
STOCK | 3.57K | $15.00K | Direct |
| Jul 1, 26 | WHOLIHAN EDWARD Director |
STOCK | 3.57K | $15.00K | Direct |
| Jul 1, 26 | FRENCH DONNA Director |
STOCK | 3.57K | $15.00K | Direct |
| Jun 30, 26 | MANKO JOSEPH M JR Director and Beneficial Owner of more than 10% of a Class of Security |
STOCK | 3.57K | $0 | Indirect |
| Jun 11, 26 | KALBERMATTEN ADAM R President |
BUY | 12.50K | $49.27K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ADAMS THOMAS EDWARD |
Chief Financial Officer | 313.44K | Conversion of Exercise of derivative security |
CASCELLA ROBERT A |
Director | 103.27K | Stock Award(Grant) |
FLETCHER R JOHN |
Director | 239.84K | Stock Award(Grant) |
FRENCH DONNA |
Director | 103.63K | Stock Award(Grant) |
KALBERMATTEN ADAM R |
Officer | 394.02K | Purchase |
MANKO JOSEPH M JR |
Director and Beneficial Owner of more than 10% of a Class of Security | — | Stock Award(Grant) |
MATIN SHAHRIAR |
Director | 106.26K | Stock Award(Grant) |
PAZDAN CHRISTOPHER |
Chief Operating Officer | 308.99K | Conversion of Exercise of derivative security |
THARBY LINDA M |
Chief Executive Officer | 620.62K | Purchase |
WHOLIHAN EDWARD |
Director | 56.43K | Stock Award(Grant) |
Fundamentals
Market cap$137.80M
Enterprise value$133.54M
Revenue (TTM)$45.11M
Gross profit$28.16M
EBITDA$-979.40K
Net income$-1.82M
EPS (TTM)$-0.04
Free cash flow$725.83K
Total cash$8.29M
Total debt$3.31M
Book value / share$0.39
Shares outstanding45.93M
Float34.41M
Short % of float2.60%
Dividend yield0.00%
Beta (5Y)0.39
Valuation & profitability ratios
Trailing P/E—
Forward P/E85.71
PEG ratio—
Price / sales—
Price / book7.67
EV / revenue2.96
EV / EBITDA-136.35
Gross margin62.43%
Operating margin5.21%
Profit margin-4.03%
Return on equity-10.52%
Return on assets-3.86%
Debt / equity18.33
Current ratio2.72
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $41.13M | $33.65M | $28.52M | $27.90M | +22.2% |
| Operating revenue | $41.13M | $33.65M | $28.52M | $27.90M | +22.2% |
| Cost of revenue | $15.52M | $12.31M | $11.81M | $12.53M | +26.1% |
| Gross profit | $25.60M | $21.33M | $16.71M | $15.37M | +20.0% |
| Research & development | $4.39M | $5.26M | $5.74M | $4.96M | -16.6% |
| Selling, general & admin | $23.38M | $21.63M | $20.37M | $20.61M | +8.1% |
| Total operating expense | $28.58M | $27.78M | $26.98M | $26.15M | +2.9% |
| Operating income | -$2.97M | -$6.45M | -$10.27M | -$10.78M | +53.9% |
| Net interest income | $293.40K | $444.64K | $561.33K | $145.59K | -34.0% |
| Pre-tax income | -$2.62M | -$6.06M | -$9.77M | -$10.68M | +56.9% |
| Tax provision | $21.89K | $2.89K | $3.97M | -$2.01M | +656.7% |
| Net income | -$2.64M | -$6.07M | -$13.74M | -$8.66M | +56.5% |
| Net income to common | -$2.64M | -$6.07M | -$13.74M | -$8.66M | +56.5% |
| Basic EPS | -0.06 | -0.13 | -0.30 | -0.19 | +53.8% |
| Diluted EPS | -0.06 | -0.13 | -0.30 | -0.19 | +53.8% |
| EBIT | -$2.97M | -$6.45M | -$10.27M | -$10.78M | +53.9% |
| EBITDA | -$2.16M | -$5.56M | -$9.40M | -$10.19M | +61.1% |
| Basic shares | 46.19M | 45.80M | 45.60M | 45.00M | +0.8% |
| Diluted shares | 46.19M | 45.80M | 45.60M | 45.00M | +0.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $8.87M | $9.58M | $11.48M | $17.41M | — | -7.4% |
| Cash & short-term investments | $8.87M | $9.58M | $11.48M | $17.41M | — | -7.4% |
| Accounts receivable | $5.89M | $5.50M | $4.05M | $3.56M | — | +7.1% |
| Inventory | $3.68M | $2.80M | $3.48M | $6.40M | — | +31.2% |
| Total current assets | $19.99M | $19.13M | $20.26M | $29.80M | — | +4.5% |
| Property, plant & equipment | $7.43M | $7.26M | $7.35M | $7.67M | — | +2.4% |
| Goodwill & intangibles | $684.84K | $730.28K | $754.36K | $787.18K | — | -6.2% |
| Total assets | $28.20M | $27.22M | $28.46M | $42.33M | — | +3.6% |
| Total current liabilities | $8.19M | $7.20M | $4.45M | $6.96M | — | +13.8% |
| Current debt | — | $271.15K | $314.34K | $433.30K | $508.58K | — |
| Total debt | $3.50M | $3.99M | $4.45M | $4.93M | — | -12.4% |
| Total liabilities | $11.15M | $10.40M | $8.11M | $11.01M | — | +7.2% |
| Retained earnings | -$32.02M | -$29.38M | -$23.31M | -$9.57M | — | -9.0% |
| Shareholder equity | $17.05M | $16.81M | $20.35M | $31.33M | — | +1.4% |
| Working capital | $11.79M | $11.93M | $15.80M | $22.84M | — | -1.1% |
| Net tangible assets | $16.36M | $16.08M | $19.60M | $30.54M | — | +1.7% |
| Shares issued | 49.81M | 49.40M | 49.09M | 48.86M | — | +0.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$2.64M | -$6.07M | -$13.74M | -$8.66M | — | +56.5% |
| Depreciation & amortisation | $810.50K | $888.47K | $870.39K | $587.14K | — | -8.8% |
| Stock-based compensation | $2.71M | $2.62M | $2.77M | $3.08M | — | +3.4% |
| Change in working capital | -$319.17K | $1.97M | $1.20M | $1.40M | — | -116.2% |
| Operating cash flow | $462.40K | -$319.72K | -$4.89M | -$5.40M | — | +244.6% |
| Capital expenditure | -$956.49K | -$1.34M | -$814.60K | -$2.80M | — | +28.7% |
| Investing cash flow | -$949.79K | -$1.33M | -$814.60K | -$2.80M | — | +28.8% |
| Share buybacks | — | — | — | — | $0 | — |
| Financing cash flow | -$221.35K | -$248.53K | -$218.87K | $279.49K | — | +10.9% |
| Free cash flow | -$494.08K | -$1.66M | -$5.71M | -$8.21M | — | +70.3% |
| End cash position | $8.87M | $9.58M | $11.48M | $17.41M | — | -7.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $12.05M | $11.76M | $10.90M | $10.40M | $10.19M | — | +2.4% |
| Operating revenue | $12.05M | $11.76M | $10.90M | $10.40M | $10.19M | — | +2.4% |
| Cost of revenue | $4.20M | $4.53M | $4.08M | $4.14M | $3.72M | — | -7.4% |
| Gross profit | $7.85M | $7.23M | $6.82M | $6.26M | $6.48M | — | +8.5% |
| Research & development | $1.07M | $1.32M | $1.14M | $933.11K | $1.19M | — | -18.8% |
| Selling, general & admin | $5.94M | $6.58M | $6.04M | $5.99M | $5.38M | — | -9.8% |
| Total operating expense | $7.22M | $8.10M | $7.36M | $7.13M | $6.79M | — | -10.8% |
| Operating income | $626.99K | -$864.92K | -$547.10K | -$867.68K | -$312.65K | — | +172.5% |
| Net interest income | $59.87K | $81.00K | $66.70K | $74.57K | $78.95K | — | -26.1% |
| Pre-tax income | $258.25K | -$807.08K | -$482.17K | -$778.12K | -$189.51K | — | +132.0% |
| Tax provision | $5.80K | $0 | $4.68K | -$150 | $17.36K | — | — |
| Net income | $252.45K | -$807.08K | -$486.86K | -$777.97K | -$206.87K | — | +131.3% |
| Net income to common | $252.45K | -$807.08K | -$486.86K | -$777.97K | -$206.87K | — | +131.3% |
| Basic EPS | 0.01 | -0.02 | — | -0.02 | 0.00 | -0.03 | +150.0% |
| Diluted EPS | 0.01 | -0.02 | — | -0.02 | 0.00 | -0.03 | +150.0% |
| EBIT | $626.99K | -$864.92K | -$547.10K | -$867.68K | -$312.65K | — | +172.5% |
| EBITDA | $837.02K | -$667.39K | -$367.93K | -$663.20K | -$103.17K | — | +225.4% |
| Basic shares | 46.08M | 46.36M | — | 46.24M | 46.19M | 45.98M | -0.6% |
| Diluted shares | 49.51M | 46.36M | — | 46.24M | 46.19M | 45.98M | +6.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $8.29M | $8.77M | $8.87M | $8.46M | $8.05M | — | -5.5% |
| Cash & short-term investments | $8.29M | $8.77M | $8.87M | $8.46M | $8.05M | — | -5.5% |
| Accounts receivable | $5.03M | $5.98M | $5.89M | $5.41M | $4.93M | — | -16.0% |
| Inventory | $4.51M | $4.48M | $3.68M | $4.41M | $3.95M | — | +0.8% |
| Total current assets | $19.51M | $20.59M | $19.99M | $19.42M | $17.58M | — | -5.2% |
| Property, plant & equipment | $6.69M | $7.19M | $7.43M | $6.90M | $7.14M | — | -7.1% |
| Goodwill & intangibles | $1.66M | $711.21K | $684.84K | $681.62K | $698.97K | — | +133.9% |
| Total assets | $27.96M | $28.59M | $28.20M | $27.10M | $25.52M | — | -2.2% |
| Total current liabilities | $7.18M | $8.85M | $8.19M | $7.83M | $6.05M | — | -18.9% |
| Current debt | — | — | — | $334.93K | — | $137.18K | — |
| Total debt | $3.31M | $3.37M | $3.50M | $3.67M | $3.47M | — | -1.7% |
| Total liabilities | $9.91M | $11.67M | $11.15M | $10.64M | $8.99M | — | -15.1% |
| Retained earnings | -$32.57M | -$32.82M | -$32.02M | -$31.53M | -$30.75M | — | +0.8% |
| Shareholder equity | $18.05M | $16.92M | $17.05M | $16.46M | $16.53M | — | +6.7% |
| Working capital | $12.33M | $11.74M | $11.79M | $11.59M | $11.53M | — | +5.1% |
| Net tangible assets | $16.39M | $16.21M | $16.36M | $15.78M | $15.83M | — | +1.1% |
| Shares issued | 46.15M | 49.95M | 49.81M | 49.73M | 49.67M | — | -7.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $252.45K | -$807.08K | -$486.86K | -$777.97K | -$206.87K | +131.3% |
| Depreciation & amortisation | $210.03K | $197.53K | $179.17K | $204.48K | $209.49K | +6.3% |
| Stock-based compensation | $457.77K | $681.51K | $972.81K | $627.39K | $415.74K | -32.8% |
| Change in working capital | -$1.11M | -$56.32K | $534.17K | $11.55K | -$878.70K | -1,868.1% |
| Operating cash flow | $216.11K | $14.66K | $1.09M | $65.46K | -$460.34K | +1,373.9% |
| Capital expenditure | -$577.37K | -$89.89K | -$428.36K | -$52.48K | -$28.81K | -542.3% |
| Investing cash flow | -$577.37K | -$89.89K | -$421.65K | -$52.48K | -$28.81K | -542.3% |
| Financing cash flow | -$118.82K | -$29.22K | -$264.91K | $396.33K | -$191.96K | -306.7% |
| Free cash flow | -$361.25K | -$75.22K | $666.40K | $12.97K | -$489.15K | -380.3% |
| End cash position | $8.29M | $8.77M | $8.87M | $8.46M | $8.05M | -5.5% |
Options analytics
Put / call volume
—
—
Put / call open interest
0.19
Positioning, not flow
Max pain
2.50
-16.7% from spot
ATM implied vol
50.0%
Nearest strike to spot
Skew (10% OTM)
-25.0%
Calls bid over puts
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
5.00
16 contracts
Heaviest put OI
2.50
3 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.01 | 0.02 | +500.0% |
| Mar 2026 | -0.01 | 0.00 | +100.0% |
| Dec 2025 | -0.01 | 0.01 | +180.0% |
| Sep 2025 | -0.02 | 0.00 | +100.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.02 | 2 | $11.33M | +8.9% |
| Next quarter | 0.00 | 2 | $12.92M | +18.6% |
| Current year | -0.01 | 2 | $48.03M | +16.8% |
| Next year | 0.04 | 2 | $56.30M | +17.2% |
Analyst targets & ownership
Mean target$6.25
High target$8.00
Low target$5.00
Implied upside108.33%
Analyst count4
ConsensusNONE
Strong buy / Buy0 / 3
Hold1
Sell / Strong sell0 / 0
Held by insiders8.21%
Held by institutions56.46%
Institutions holding116
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
3.07
-2.39% from price
SMA 20
3.13
-4.28% from price
SMA 50
3.35
-10.54% from price
SMA 100
3.73
-19.57% from price
SMA 200
4.27
-29.75% from price
EMA 12
3.07
-2.28% from price
EMA 26
3.17
-5.34% from price
EMA 50
3.35
-10.38% from price
RSI (14)
36.2
Neutral
MACD (12,26,9)
-0.10
Hist -0.01
ATR (14)
0.16
5.19% of price
Realised vol 30D
25.9%
Annualised
Bollinger upper
3.36
20, 2σ
Bollinger lower
2.91
20, 2σ
50 / 200 cross
Death
3.35 vs 4.27
Trend bias
Below 200
-29.75%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.55
Less volatile than market
Correlation to SPY
0.15
Largely independent
Realised vol 30D
25.9%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-55.1%
Peak to trough
Max drawdown 5Y
-58.0%
Peak to trough
ATR 14
0.16
5.19% of price
Beta (reported)
0.39
5Y monthly, from filing
Short interest
Shares short
984.59K
Prior 779.25K
Change vs prior
+26.4%
Shorts adding
% of float
2.60%
Normal
% of shares out
2.13%
Against total outstanding
Days to cover
5.4
Crowded exit
Float
34.41M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 13, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Mar 13, 26 | B. Riley Securities | MAINTAINED | Buy | Buy |
| Dec 22, 25 | Lake Street | MAINTAINED | Buy | Buy |
| Dec 17, 25 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Aug 7, 25 | Piper Sandler | MAINTAINED | Neutral | Neutral |
| May 8, 25 | Piper Sandler | MAINTAINED | Neutral | Neutral |
| Feb 14, 25 | Piper Sandler | DOWNGRADE | Overweight | Neutral |
| Jan 17, 25 | Craig-Hallum | MAINTAINED | Buy | Buy |
| Jan 14, 25 | Lake Street | MAINTAINED | Buy | Buy |
| Nov 14, 24 | Craig-Hallum | MAINTAINED | Buy | Buy |
| Nov 14, 24 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Nov 14, 24 | Piper Sandler | MAINTAINED | Overweight | Overweight |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-14
Periodic Financial Reports
10-Q · 2026-08-05
Corporate Changes & Voting Matters
8-K · 2026-06-30
Corporate Changes & Voting Matters
8-K · 2026-05-21
Periodic Financial Reports
10-Q · 2026-05-06
Proxy Statements
DEF 14A · 2026-04-09
Corporate Changes & Voting Matters
8-K · 2026-04-03
Corporate Changes & Voting Matters
8-K · 2026-03-16
Headlines
Reasons to Retain Doximity Stock in Your Portfolio for Now
Zacks · 2d ago
KORU (KRMD) Q2 2026 Earnings Call Transcript
Motley Fool · 56d ago
KORU Medical Systems Inc (KRMD) (Q2 2026) Earnings Call Highlights: Record Revenue and First ...
GuruFocus.com · 62d ago
KORU Medical Systems Q2 Earnings Call Highlights
MarketBeat · 62d ago
KORU Medical Systems, Inc. Q2 2026 Earnings Call Summary
Moby · 62d ago
KORU Medical Systems, Inc. (KRMD) Q2 Earnings and Revenues Beat Estimates
Zacks · 63d ago
KORU Medical Systems Announces Second Quarter 2026 Results and Updates Full Year 2026 Guidance
Business Wire · 63d ago
Earnings To Watch: KORU Medical Systems Inc (KRMD) Q2 2026 -- GF Value Sees 15% Upside
GuruFocus.com · 64d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.